What You Should Know:
– 23andMe Holding Co. (Nasdaq: ME), a genetics and biopharmaceutical company, announced The U.S. Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for 23ME-01473 (referred to…
Continue Reading
Sano Genetics has raised $11.4m in a new funding round to help power a revolution in precision medicine by deploying artificial intelligence to help streamline the clinical trial process.The Cambridge-based company is building a…
Continue Reading
What You Should Know:
– Invitae (NYSE: NVTA), a medical genetics company, announced the completion of its sale of certain reproductive health assets, including carrier screening and non-invasive prenatal screening (NIPS), to Natera (NASDAQ: NTRA).
–…
Continue Reading
What You Should Know:
– Sano Genetics, a software company that is revolutionizing precision medicine research, has secured $11.4M in new funding.
– This latest investment, led by Plural with participation from existing investors MMC Ventures,…
Continue Reading
Top News
Medical genetics company Invitae divests its Ciitizen patient-controlled health data business to that company’s leadership team and a group of investors who will operate it as an independent company. Terms were not disclosed….
Continue Reading
Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform…
Continue Reading
Streamlining engagements, simplifying jargon, and enhancing adherence, AI transforms healthcare experiences. From online scheduling optimization to personalized care plans based on genetics, it fosters tailored, empathetic communication. Proactive outreach, powered by AI, ensures no…
Continue Reading
What You Should Know:
– 23andMe has launched 23andMe+ Total Health, a comprehensive prevention-based health membership.
– Total Health provides clinical-grade exome sequencing, biannual blood testing, genetics-based clinical care, and access to clinicians trained in genetics.
Comprehensive,…
Continue Reading
Researchers at the University of Massachusetts Amherst have developed a new method of detecting very small amounts of DNA. The breakthrough could allow clinicians to spot genetic markers of disease at the point-of-care, as…
Continue Reading
Scientists at Purdue University have developed a microRNA therapy designed to slow tumor growth. The technology takes advantage of the tendency of several cancer types to express an excess of surface receptors that bind…
Continue Reading
